Locations:
Search IconSearch
April 6, 2021/Cancer

Conscious Sedation for Endoluminal Colorectal Procedures a Game-Changer

“It’s better for everyone,” surgeon says.

Endoluminal Surgery

Cleveland Clinic is pioneering the use of advanced endoscopic techniques to remove complex polyps and early malignant lesions in the digestive tract without anesthesia. Selected colorectal procedures are now performed under conscious sedation in the outpatient Endoluminal Surgery Center.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“We prefer to use conscious sedation when removing benign polyps and early malignant lesions that are low-risk for metastasis. Patients prefer it, outcomes are improved and procedures are less expensive,” says Cleveland Clinic colorectal surgical oncologist and endoluminal surgery pioneer Emre Gorgun, MD. “It’s really better for everyone.”

Conscious sedation is less risky than sedation with propofol or general anesthesia, particularly for patients with heart disease or other comorbid condition presenting for gastrointestinal surgery.

“Patients are able to roll over or move as requested and can adjust their own body position to remain comfortable. They awaken easily and quickly regain their balance and stability, making same-day homegoing safer,” he says.

Rapidly advancing field

Expansion of screening protocols has increased the number of patients diagnosed with nonmalignant lesions or early cancers of the colon and rectum. Traditionally, such patients are referred for surgery. The availability of endoluminal surgery and natural orifice approach is allowing a growing percentage of patients with complex colon polyps, large duodenal polyps, early esophageal cancers, gastric cancers and neuroendocrine tumors to undergo less-invasive treatment.

“In our practice, the risk of recurrence is low at 2 to 3%,” says Dr. Gorgun. “Because these patients may be at high risk for recurrence, we do a repeat scope and surveillance at six months, then follow up every three years.”

Early cancers can be managed endoluminally, so long as lymph node involvement is negligible or nonexistent.

Advertisement

“We resect these lesions en bloc and measure the depth of invasion. If it is less than 1000 micrometers, all is well. With deeper lesions the risk of lymph node involvement rises, and organ resection becomes more appropriate,” he explains.

Lesions that may leave a large defect when removed are selectively scheduled for endoscopic surgery with laparoscopic backup.

Looking ahead

Dr. Gorgun foresees the rapid expansion of endoluminal surgery as operators gain experience and devices evolve to handle increasingly complex lesions.

Several models for learning the technique have been developed, and Dr. Gorgun offers courses at Cleveland Clinic and at national meetings. “It is demanding on operators’ skills, so the learning curve is fairly steep,” he says.

Cleveland Clinic is partnering with device manufacturers to improve the tools needed to refine endoluminal surgery, including better scopes, tools that will facilitate endoscopic suturing and more dexterous robots. “They will make suturing safer and enable us to tackle much larger lesions,” he says.

Dr. Gorgun feels that interest in endoluminal surgery will accelerate once the sentinel lymph node for metastatic cancers is discovered. “Sentinel lymph node biopsy is key,” he says. “Currently in this country, for every four colons removed for cancer, one is removed for a nonmalignant lesion. When we discover the sentinel node, endoluminal surgery will become even more useful.”

Advertisement

Related Articles

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Ad